STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMNN
  4. [Form 4] Imunon, Inc. Insider Trading Activity

Imunon (IMNN) counsel granted, then sells 2,150 shares of Common Stock

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Imunon, Inc. executive Susan Eylward, General Counsel and Corporate Secretary, reported two Common Stock transactions. On 2026-07-17, she received 2,150 shares at $1.8300 per share as stock granted in lieu of a portion of base salary. On 2026-07-20, she sold 2,150 shares at a weighted average price of $1.7816 per share, with individual sale prices ranging from $1.76 to $1.79. The filing indicates these trades were not made under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider Eylward Susan
Role General Counsel and Corp Sec
Sold 2,150 shs ($4K)
Type Security Shares Price Value
Sale Common Stock F2 2,150 $1.7816 $4K
Grant/Award Common Stock F1 2,150 $1.83 $4K
Holdings After Transaction: Common Stock — 2,896 shares (Direct)
Footnotes (2)
  1. F1. Stock granted in lieu of cash for portion of base salary
  2. F2. Reflects a weighted average sale price of $1.7816 per share, at prices ranging from $1.76 to $1.79 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.
Shares sold 2,150 shares Sale of Common Stock on 2026-07-20
Weighted average sale price $1.7816 per share Common Stock sale on 2026-07-20; prices from $1.76 to $1.79
Sale price range $1.76 to $1.79 per share Price range for 2026-07-20 Common Stock sales
Shares granted 2,150 shares Stock granted in lieu of cash salary on 2026-07-17
Grant price $1.8300 per share Common Stock granted on 2026-07-17 as salary-related stock
weighted average sale price financial
"Reflects a weighted average sale price of $1.7816 per share"
in lieu of cash financial
"Stock granted in lieu of cash for portion of base salary"
open market or private transaction financial
"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Imunon (IMNN) report for Susan Eylward?
Imunon (IMNN) reported that Susan Eylward received 2,150 shares of Common Stock on 2026-07-17 as stock in lieu of salary, then sold 2,150 shares on 2026-07-20 at a weighted average price of $1.7816 per share.

How many Imunon (IMNN) shares did Susan Eylward sell and at what prices?
She sold 2,150 shares of Imunon (IMNN) Common Stock on 2026-07-20 at a weighted average price of $1.7816 per share, with individual trade prices ranging from $1.76 to $1.79 per share.

What was the nature of the 2,150-share grant to Susan Eylward at Imunon (IMNN)?
On 2026-07-17, Susan Eylward received 2,150 shares of Imunon (IMNN) Common Stock at $1.8300 per share as stock granted in lieu of cash for a portion of her base salary, representing compensation rather than an open-market purchase.

Were Susan Eylward’s July 2026 Imunon (IMNN) trades under a Rule 10b5-1 plan?
No. The Form 4’s Rule 10b5-1 checkbox is unchecked, indicating Susan Eylward’s July 2026 Imunon (IMNN) transactions were not reported as being made pursuant to a Rule 10b5-1 trading plan.

What type of security was involved in Susan Eylward’s Imunon (IMNN) Form 4?
All reported transactions involve Imunon (IMNN) Common Stock. The Form 4 shows a grant of 2,150 shares as salary-related stock compensation and a subsequent sale of 2,150 shares, with no derivative securities reported.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Eylward Susan
(Last)(First)(Middle)
C/O IMUNON, INC.
997 LENOX DRIVE, SUITE 100
(Street)
LAWRENCEVILLE NEW JERSEY 08648
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
General Counsel and Corp Sec
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/17/2026A2,150(1)A$1.835,046D
Common Stock07/20/2026S2,150D$1.7816(2)2,896D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Stock granted in lieu of cash for portion of base salary
2. Reflects a weighted average sale price of $1.7816 per share, at prices ranging from $1.76 to $1.79 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.
/s/ Susan Eylward07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR